BTIG analyst Justin Zelin has maintained their bullish stance on TCRX stock, giving a Buy rating on August 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Zelin has given his Buy rating due to a combination of factors that highlight TScan Therapeutics’ promising developments and strategic advancements. The company is on track to deliver 2-year relapse data for its TSC-101 program by the end of 2025, which has shown favorable results in previous trials, significantly outperforming the control arm in terms of relapse rates and event-free survival. This progress, despite challenges at the FDA, indicates a strong potential for TSC-101 in treating conditions like AML, ALL, and MDS.
Furthermore, TScan is preparing to start a pivotal study for TSC-101 in the second half of 2025, with data expected by the second half of 2027. The use of a synthetic control arm, which has been agreed upon by the FDA, is seen as a strategic advantage, allowing for better patient matching and addressing ethical considerations. Additionally, the company’s efforts in the solid tumor space, particularly with its multiplex TCR-T therapy, are progressing with initial data expected in early 2026. These developments, combined with a robust valuation approach, underpin Zelin’s optimistic outlook for TScan Therapeutics.
In another report released on August 13, Barclays also maintained a Buy rating on the stock with a $3.00 price target.
TCRX’s price has also changed moderately for the past six months – from $2.110 to $1.670, which is a -20.85% drop .